Tuesday, December 30, 2008

GTx Submits New Drug Application for Toremifene 80 mg for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy

Dec 30, 2008 - GTx, Inc. today announced the submission of a New Drug Application with the U.S. FDA for toremifene 80 mg, an oral selective estrogen receptor modulator (SERM), for the prevention of bone fractures in men with prostate cancer on androgen deprivation therapy.

The details can be read here.

No comments: